胃泌素抑制肽(GIP)多克隆抗體
Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP)
Incretin hormone; Glucose Dependent Insulinotropic Peptide
- 編號PAA882Ra08
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 616 ¥ 1436 ¥ 2052 ¥ 5130 ¥ 20520
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對GIP的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別GIP。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學：5-20μg/mL;1:25-100
免疫細胞化學：5-20μg/mL;1:25-100
最佳稀釋倍數最終由用戶決定。
儲存
經常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩定性
熱穩定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
贈品
增值服務
相關產品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA882Ra01 | 胃泌素抑制肽(GIP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPA882Ra11 | 胃泌素抑制肽(GIP)牛血清白蛋白偶聯物 | Immunogen; SDS-PAGE; WB. |
| CPA882Ra21 | 胃泌素抑制肽(GIP)卵白蛋白偶聯物 | Immunogen; SDS-PAGE; WB. |
| PAA882Ra08 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA882Ra01 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA882Ra21 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC; ICC; IP. |
| MEA882Ra | 胃泌素抑制肽(GIP)檢測試劑盒(酶聯免疫吸附試驗法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEA882Ra | 胃泌素抑制肽(GIP)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA882Ra | 胃泌素抑制肽(GIP)等多因子檢測試劑盒(流式熒光發光法) | FLIA Kit for Antigen Detection. |
| KSA882Ra11 | 胃泌素抑制肽(GIP)檢測試劑盒DIY材料(酶聯免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Scientific Reports | The?anti-hyperglycemic?efficacy?of a?lipid-lowering?drug?Daming?capsule?and the?underlyingsignaling?mechanisms?in a?rat?model?of?diabetes?mellitus. [pubmed:27721485] |
| Obesity surgery | The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats. [pubmed:28840471] |
| Obesity?Surgery? | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague?… [Pubmed:29098544] |
| BioMed Research International | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity [] |
| Diabetes Research and Clinical Practice | Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients [Pubmed: 31734225] |
| OBESITY SURGERY | The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats [Pubmed: 31701411] |
| FUTURE SCIENCE | Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes [Pubmed:35251693] |
留言咨詢
